Control is the aim of asthma management and clinical trials show that control can be achieved in the majority of patients. However, population surveys show that poorly controlled asthma still imposes a considerable burden. This fact has led to a re-evaluation of the international asthma guidelines and the updated 2006 and 2007 GINA and NAEPP guidelines suggest that the level of control should be used as the key feature for the classification and management of asthma. Furthermore, in the latest guidelines, a clearer definition of control is given and new tools for the assessment and monitoring of control are instituted. In order to achieve asthma control, not only relevant pharmacological treatment but, the establishment of a good patient-doctor relationship, proper education of the asthmatic patient, reduction of exposure to triggers and treatment of co-morbidities are pivotal issues and must be ensured.
Introduction
Asthma is a chronic disease that can be managed but not eradicated. The aim, therefore, of asthma management is control (Barnes, 2005) . The definition of control in asthma is not however a simple and clear target as in many chronic diseases: for example, in hypertension the upper limits for systolic and diastolic blood pressure are set to 140 and 90 mmHg respectively. Similarly, in diabetes the limit for HbA1c is set to 7% or less. Obviously, very low levels and side effects should be avoided but still, the aim of treatment is rather simple. In asthma, such simple and uniform targets or limits do not exist and a composite score is necessary for the assessment of control, which is reached when the patient has no daytime or nocturnal symptoms, no limitations of activity, no need for rescue medication, normal lung function and no exacerbations. In order to achieve control, detailed assessment of the patient and the provision of tailored management instructions and treatment are needed.
Guidelines have been published, prompting the use of a multitude of indicators, such as symptoms, lung function, history and standardized questionnaires to facilitate this assessment and guide treatment. Guidelines also stress the importance of a good patient-doctor relationship, of patient education and the active involvement of the thus informed and educated patient in management decisions (GINA, 2007; NAEPP, 2007) .
The aim of this review is to describe the cur-Correspondence to: rent tools for the assessment of control and the importance of this assessment in the provision of tailored management plans.
Assessment and monitoring
In the past, guidelines stressed assessment and monitoring of asthmatic patients on the basis of disease severity (Anonymous, 2003; Li et al. 1998; Anonymous, 1991) . However, severity is an endogenous component of the disease in which the physician may have little influence and therefore, monitoring patients on its basis provides limited help in clinical practice (Sawyer et al. 1998; Cockcroft and Swystun, 1996) . Moreover, the use of severity as an outcome measure has limited value in predicting which treatment will be required and what the response to that treatment might be (Kwok et al. 2006 ). On the other hand, control represents the clinical manifestations of asthma and the responsiveness to treatment and therefore assessment of control provides much better guidance in the care of asthma patients (Bateman, 2006; Stoloff and Boushey, 2006) . Current guidelines suggest that severity classification should be used for the initial assessment of the patient and should be kept in mind as an important characteristic of the patient. However, assessment of control should be used for monitoring of the patient in long term follow up Table 1 . Classification of asthma according to control (adapted from NAEPP guidelines (NAEPP, 2007) ).
Components of control
Classification of asthma control (youths ≥12 years of age and adults) and the level of control should guide treatment (GINA, 2007; NAEPP, 2007) . Control can be assessed on the basis of the limitations that the disease imposes on the patient (impairment) and the future risk for his/her health (risk) ( Table 1) .
As is stressed in the NAEPP guidelines (NAEPP, 2007) , impairment should be assessed and measured on the basis of lung function tests and patient-reported symptoms, use of rescue bronchodilators and limitations of activities, while risk should be assessed on the basis of the patient's history regarding the frequency and severity of exacerbations, the rate of lung function decline and the presence of treatment side effects. Patientreported symptoms and limitations are best assessed with the use of validated asthma control questionnaires.
Currently, three standardized questionnaires are recommended by the NAEPP guidelines, the Juniper Asthma Control Questionnaire (ACQ) (Juniper et al. 1999) , the Asthma Control Test (ACT) (Nathan et al. 2004 ) and the Asthma Therapy Assessment Questionnaire (ATAQ) (Vollmer et al. 1999) . These consist of several questions, each carrying a score. The sum of the score provides a numerical value that helps define control. The oldest, most used and better validated is the ACQ (Juniper et al. 2006) but all questionnaires are valuable and currently the ACT is also extensively used (Schatz et al. 2006) .
Besides symptoms, lung function and questionnaires, markers of inflammation can be used to assess the response to treatment, predict exacerbations and prompt treatment changes to prevent these exacerbations (Scichilone et al. 2004) . The serial measurement of these markers is not included in the guidelines, as testing is time consuming and expensive and also not available in everyday clinical practice. Therefore, so far, such markers have only been used in research settings and in specialized centres. Some have been shown to help and these include induced sputum eosinophils, evaluation of BHR and exhaled
Review NO: the AMPUL study showed that the use of serial measurements of BHR can help the early prediction of an upcoming exacerbation (Sont et al. 1999) . The researchers increased ICS dosing when their patients' BHR was increased and this led to fewer exacerbations. It also led to overall increases in ICS dosing. In another widely quoted study, Green et al. (2002) showed that increases in eosinophils in the serial examination of induced sputum eosinophils can help predict exacerbations. These authors also increased ICS dosing when sputum eosinophils increased and this strategy led to fewer exacerbations compared to the control group. Both these measurements however are time consuming and require a specialized setting. Exhaled NO (eNO) serial measurements may also prove helpful and increased eNO has also been shown to be an early marker of exacerbation and loss of control (Michils et al. 2007) . As eNO measurement is quick and it is becoming less expensive and more widely available through the use of less expensive hand-held devices (Menzies et al. 2007 ), this may be a marker that will be more widely used in clinical practice.
Data on the current level of control
Numerous large population-based surveys have been published, some quite recently, and they show rather disappointing results regarding asthma control and asthma management. The AIRE (Asthma Insights and Reality in Europe) study published in 2000 was carried out to assess the level of asthma control in 7 European countries (Rabe et al. 2000) . It used a survey questionnaire based on the ATS questionnaire and was administered via phone calls. A total of 2803 people with asthma were interviewed and the conclusion was that the current level of asthma control falls far short of the goals for long-term asthma management. More than half (56%) of the respondents had suffered daytime symptoms in the last 4 weeks, around one in three respondents had experienced sleep disruption due to asthma at least once a week and only 5.1% of adult asthmatics met all criteria for asthma control according to the definition published in the 1995 GINA guidelines. In the same period of time a national population survey in the US, the Asthma in America study (Fuhlbrigge et al. 2002 ). 41% of asthmatic patients stated that asthma limited their ability to do their daily activities to a great extent, while over a quarter reported unscheduled healthcare contacts and approximately 10% visited the Emergency Department due to an asthma attack in the previous year. Similar results indicating poor asthma control even in asthmatic patients under specialist care were published a few years ago (Gaga et al. 2005) . 378 randomly selected patients with mild/moderate asthma were studied and results showed that the majority had symptoms and limitations to their physical and social activities and had frequent exacerbations, while >40% of patients thought that their asthma was not well controlled.
An interesting review of asthma patient surveys in Europe and North America, was published almost a year ago (Holgate et al. 2006) . Twenty four surveys including a total of 57,817 patients from 24 countries were considered in the final analysis. Results indicated that patients often experienced high levels of asthma symptoms even while receiving asthma therapy. Diurnal symptoms were reported by 46-75% and nocturnal symptoms by 30-70% of the patients.
All these data indicate that the goals of asthma treatment are not achieved on a worldwide level, even in the most advantageous settings, i.e. in countries with excellent standards of care and in spite of the widespread use of new effective treatments (new inhaled steroid preparations, long acting beta agonists, fixed combination inhalers, anti-leukotrienes, anti-IgE) and the numerous international asthma guidelines updated frequently and focusing until recently in asthma severity-based management and plans. Moreover, surveys showed that patients do not have the same perspective as their doctors and they experience and define the level of control and the impact of asthma on their lives differently from their treating physician (Holgate et al. 2006) . As the aim of asthma is control and this includes the patient's experience and feeling, the international scientific community and asthma experts had to re-consider their position regarding asthma management. Therefore, the current guidelines include these two important changes: (a) asthma management is based on asthma control and (b) the patient is central in all discussions and decision making regarding what he/she needs and what he/she defines as control of disease and as the ultimate goal in asthma management. Control was always the goal of asthma management but now becomes the core issue in all guidelines (GINA, 2007; NAEPP, 2007) ; asthma is classified according to level of control and treatment is guided according to level of control. Moreover, a clearer definition of asthma control is given and a standardized and validated estimation can be helped, not only with lung function but also the use of validated questionnaires.
Patient-doctor relationship
The effective management of asthma requires the development of a partnership between the person with asthma and his or her health care professional(s). The aim of this partnership is control of asthma, i.e. asymptomatic patients able to carry out any activity. This aim is best achieved through guided self-management and a good patient-doctor relationship-partnership. The partnership is formed and strengthened as patients and their health care professionals discuss the patient's needs, worries and expectations, agree on the goals of treatment, develop a personalized, written self-management plan and periodically review the patient's treatment and level of asthma control (Bateman et al. 2008) . To achieve this, the doctor/healthcare professional needs to spend time with the patient, get to know his feelings and, if needed, use this knowledge to change the patient's beliefs and answer his worries. Surveys have repeatedly shown that patients feel they don't have enough time with their doctor and that their concerns and needs are not taken into consideration (Moffat et al. 2006) . Moreover, surveys also show that patients underestimate their symptoms and disease severity, have low expectations and worry about long-term side-effects of medication beliefs that lead to poor compliance . So doctors must address all these issues, which are different for each patient and this requires knowing the patient well.
This partnership allows the patient a very active role in his management and it takes the doctor away from the role of unquestionable authority that single-handedly provides prescriptions. The role of the physician is to provide the patient with the knowledge about his disease and the principles of management and to help the patient set his treatment plans ensuring that the level of control is good. Education should be an integral part of all interactions between health care professionals and patients, and is relevant to asthma patients of all ages. Personal asthma action plans help individuals with asthma make changes to their treatment in response to changes in their level of asthma control, as indicated by symptoms and/or peak expiratory flow, in accordance with written predetermined instructions .
Education
The Review adverse effects ). Newer medications, especially newer inhaled steroids are safer and have fewer side effects (Cerasoli Jr, 2006) but the majority of patients remain reluctant to take them regularly. Doctors and health care professionals need to spend time with the patient, explain what asthma is, what causes it, how to prevent exposure, why and when medication should be taken, discuss the patient's concerns and fears and explain the importance of regular intake of controlling medications. Educational interventions should be structured and repeated: Cote et al. (2001) showed that a repeated and structured educational intervention increased long-term adherence to treatment from 20% to almost 70%.
Education and support may also be provided through peer-support groups and the family.
Internet-based education currently also plays a role and it will become more pronounced in the future. It is very important to provide our patient with trustworthy and validated links such as the European Lung Foundation (ELF) and the European Federation of Allergy (EFA) sites.
Reduction of exposure and treatment of co-morbidities
Although pharmacologic intervention to treat established asthma is highly effective in controlling symptoms and improving quality of life, measures to prevent the development of asthma, asthma symptoms and asthma exacerbations such as avoiding or reducing exposure to risk factors should be implemented wherever possible.
Asthma exacerbations may be caused by a variety of factors, sometimes referred to as 'triggers', including allergens, viral infections, pollutants, and drugs. Reducing a patient's exposure to some of these risk factors (e.g., smoking cessation, reducing exposure to secondhand smoke, reducing or eliminating exposure to indoor allergens, occupational agents known to cause symptoms, and avoiding foods/additives/drugs known to cause symptoms) improves control of asthma and reduces medication needs (Chaudhuri et al. 2006; Custovic et al. 2002; Peroni et al. 2002) .
Other factors such as outdoor allergens, viral infections and atmospheric pollutants are much more difficult and often impractical to control. Measures such as influenza vaccination (Bueving et al. 2004) should be taken and environmental control policies such as emission and exhaust fume reduction should be urged from governments (Persky et al. 2007) . Nevertheless, many triggering factors are ubiquitous in the environment and avoiding these factors is usually both impractical and also very limiting to the patient. For example, in order to avoid exposure to grass pollen, a patient should stay indoors or wear a cumbersome and strange looking face mask throughout the spring. Both solutions are impossible or impractical and in this case, an increased dosing of medications should be provided to maintain asthma control.
Concomitant diseases may exacerbate asthma and should be addressed. Ten Brinke et al. (2005) showed that rhinosinusitis, gastro-esophageal reflux, psychological disorders, hormonal disorders, obesity and sleep-apnea are important risk factors for exacerbations and should be treated. Similar results were shown in the TENOR study of severe asthma and, based on data from the TENOR cohort, a risk score for severe exacerbations has been calculated (Lee et al. 2007 ). The risk is higher when patients are obese, have diabetes, cataracts, a previous history of pneumonia, previous history of intubation and poor lung function. Race, age and gender are also important risk factors. Figure 1 shows the current GINA guidelines on asthma pharmacological treatment which is based on the level of asthma control. For the physician who is not used to treating asthmatic patients, it may be a little difficult to relate a 3 level classification of control with a 5 scale classification of treatment. However, initial treatment is based on asthma severity and subsequent changes in medication are based on the level of control: the patient remains at the initial medication level or medication is stepped up or down according to the level or control. Therefore, if at the initial examination the patient is considered mild, he can be started on level 1 or 2 and if he is considered moderate/severe, on level 3 or 4. At a subsequent visit, a patient who is controlled at level 4 may be stepped down to level 3 or conversely, a patient uncontrolled on step 4 should be stepped up to step 5. When deciding about the initial ICS dosing, some physicians prefer to start at a slightly high dose and then step down once control has been achieved. On the other hand, some prefer to start with a low dose and step up if control is not achieved. dose helps achieve control earlier but that high doses are not necessary for long term control Chanez et al. 2001; van der Molen T. et al. 1998 ). So whether starting high or low, it is necessary to monitor the patients closely, at least initially. Long term, we should aim to step down to the lowest dose that maintains control. However, it is important to make an early diagnosis of loss of control and of an upcoming exacerbation and promptly institute step-up medication doses. Newer data show that early institution of ICS on demand (in combination with SABA or LABA) at the appearance/worsening of symptoms may be effective (Papi et al. 2007) . The use of the combination of budesonide and formoterol as rescue medication is currently included as an option in the GINA guidelines. As more studies are published (Papi et al. 2007; Rabe et al. 2006) , the use of on demand ICS as rescue medication may be included in the guidelines. Smoking reduces the effectiveness of ICS (Lazarus et al. 2007 ) and
Pharmacologic treatment
Review non-smoking strategies should always be urged. Leukotriene antagonists may possibly help control in smoking asthmatics (Lazarus et al. 2007; Rabe et al. 2006) . In severe IgE-mediated asthma, the use of omalizumab has proved to be effective (Bousquet et al. 2005) .
Conclusions
To assess and monitor asthma control and prognosis we need to assess severity, ensure regular follow up, provide education and speak the same language with our patients. Moreover, to ensure that the goal of asthma treatment is achieved, we must define the needs, expectations and worries of each individual patient, agree on the levels of control/treatment level and medication doses that are acceptable to the patient as well as ourselves and institute individualized management plans. Very importantly, we must give the patient initiative and freedom within the limits of good medical practice.
